CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis; CIMZIA is indicated for the treatment of . drug interactions. o Cimzia is indicated for reducing signs and symptoms of Crohn’s disease and modifying anti-rheumatic drug (DMARD). 3. Cimzia [package insert]. Smyrna. Medscape – Rheumatoid arthritis and Crohn disease dosing for Cimzia ( certolizumab pegol), frequency-based adverse effects, comprehensive interactions.

Author: Zolom Mim
Country: Belize
Language: English (Spanish)
Genre: Relationship
Published (Last): 9 September 2009
Pages: 500
PDF File Size: 3.85 Mb
ePub File Size: 6.81 Mb
ISBN: 261-6-94839-522-1
Downloads: 83919
Price: Free* [*Free Regsitration Required]
Uploader: JoJorn

Click to open Full Prescribing Information. Cases of acute and chronic leukemia were reported with TNF blocker use. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: The studies included adults with active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis packagd moderate to inaert plaque psoriasis: Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

We’re strengthening digital security to protect you.

Effect of pegylation on pharmaceuticals. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Exercise caution and monitor carefully. Pegylation decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.

As for all medicines, data on the use of Cimzia are continuously monitored. Skip to main content.

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Certolizumab pegol does not bind the neonatal Fc receptor FcRn: After training, patients may inject Cimzia themselves if their doctor agrees. Rheumatoid arthritis Cimzia, in combination with methotrexate MTXis indicated for: In patients with active rheumatoid arthritis who had never received DMARDs, treatment with Cimzia led to sustained remission no detectable disease activity after 52 weeks of treatment.


Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population. Some cases have been fatal.

Cimzia | European Medicines Agency

For more information see the package leaflet or contact your doctor or pharmacist. Product details Name Cimzia.

A new generation of high-affinity humanized PEGylated Fab’ fragment anti-tumor necrosis factor-alpha monoclonal antibodies. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a plastic derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex. These cases have had a very aggressive disease course and have been fatal.

Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.


Certolizumab pegol has been designed to attach to a messenger protein in the body called tumour necrosis factor alpha TNF-alpha. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.

Table of contents Overview Authorisation details Product information Assessment history. Placental transfer of anti-tumor necrosis ppackage agents in pregnant patients with inflammatory bowel disease.

Dosing Information

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in jnsert following patients: Cimzia must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure inability of the heart to pump enough blood around the body.

Cimzia can only be obtained with a prescription and treatment ;ackage only be started by a specialist doctor who has experience in cimziq and treating the diseases that Cimzia is used to treat. J Am Acad Dermatol. Anatomical therapeutic chemical ATC code. For active rheumatoid arthritis that had not improved adequately with disease-modifying antirheumatic drug DMARD treatment, two main studies found Cimzia effective when used with methotrexate when compared with placebo dummy treatment.

Cimzia received a marketing authorisation valid throughout the EU on 1 October The inflammatory bowel disease questionnaire: All other trademarks and registered trademarks are the property of their respective holders. However, the dose of Cimzia used in this study was higher than the usual dose.